Is Cosentyx an Injectable or a Pill?
Cosentyx (secukinumab) is an injectable biologic drug, not a pill. It's administered via subcutaneous injection using pre-filled syringes, auto-injectors (Sensoready pen), or vials for healthcare provider use.[1][2]
How Is Cosentyx Injected?
Patients typically self-inject under the skin in the thigh, abdomen, or upper arm. The standard loading dose is 300 mg (two 150 mg injections) at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks for plaque psoriasis. Doses vary by condition (e.g., 150 mg monthly for psoriatic arthritis). Training is provided for home use.[1][3]
Why No Pill Form?
Cosentyx is a monoclonal antibody protein that would break down in the stomach if taken orally. Injection bypasses digestion to deliver it intact into the bloodstream.[4]
Conditions Treated with Cosentyx
FDA-approved for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa in adults and children.[1]
Common Side Effects from Injections
Injection site reactions (redness, itching), upper respiratory infections, diarrhea, and increased infection risk. Rare risks include tuberculosis reactivation or inflammatory bowel disease.[1][2]
How Cosentyx Compares to Oral Alternatives
Unlike pills like Otezla (apremilast) for psoriasis or methotrexate, Cosentyx targets IL-17A more precisely but requires injections. Oral JAK inhibitors (e.g., Rinvoq) offer pill convenience with broader immune suppression and black-box warnings for clots, cancer, and infections.[5]
[1] Cosentyx Prescribing Information (Novartis)
[2] FDA Label for Secukinumab
[3] Cosentyx Dosing Guide
[4] IL-17 Inhibitors Mechanism (NEJM Review)
[5] Psoriasis Treatment Comparisons (AAD)